Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimbu, Laura, Mesaros, Oana, Popescu, Cristian, Neaga, Alexandra, Berceanu, Iulia, Dima, Delia, Gaman, Mihaela, Zdrenghea, Mihnea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063836/
https://www.ncbi.nlm.nih.gov/pubmed/33804850
http://dx.doi.org/10.3390/ph14040288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063836/
https://www.ncbi.nlm.nih.gov/pubmed/33804850
http://dx.doi.org/10.3390/ph14040288

Ejemplares similares